Related Experiment Video
Updated: Jul 13, 2026
11:37
Cellular Redox Profiling Using High-content Microscopy
Published on: May 14, 2017
Interactions between protease inhibitors and acid-reducing agents: a systematic review
L Béïque1, P Giguère, C la Porte
1Ottawa Health Research Institute, Ottawa, Ontario, Canada. lbeique@ottawahospital.on.ca
HIV Medicine
|July 31, 2007
Summary
Most protease inhibitors (PIs) show no significant drug interaction with acid-reducing agents, based on pharmacokinetic data. However, limited clinical data exists, particularly for atazanavir interactions.
Area of Science:
- Pharmacology
- Drug Interactions
- Gastroenterology
Background:
- Protease inhibitors (PIs) are crucial in treating viral infections.
- Acid-reducing agents are commonly used for gastrointestinal issues.
- Potential drug interactions between PIs and acid-reducing agents require investigation.
Purpose of the Study:
- To systematically review pharmacokinetic and clinical data on drug interactions between PIs and acid-reducing agents.
- To assess the clinical relevance of these drug interactions.
Main Methods:
- Comprehensive literature search of Medline and EMBASE databases.
- Inclusion of abstracts from major conferences within the last two years.
- Contacting manufacturers for drug information on available PIs.
- Data summarization and verification by at least two authors.
Main Results:
- Identified 1231 references; 22 focused on pharmacokinetic interactions between PIs and acid-suppressive agents.
- An additional 12 studies provided pharmacokinetic and/or clinical data.
- Many pharmacokinetic studies indicated no significant drug interaction with most PIs.
Conclusions:
- Pharmacokinetic data suggests a lack of significant drug interaction between most PIs and acid-reducing agents.
- Limited clinical data is available, with notable exceptions for atazanavir interactions.
- The complexity of these interactions may explain the scarcity of clinical information.
Related Concept Videos
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:31Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
However, this neutralization reaction between...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...